NTRK1 and cancer: The identification of fusion driver oncogenes with aberrant tyrosine kinase activation, such as ALK, ROS1, RET, or NTRK1 rearrangement in cancers, is largely changing therapeutic strategies accompanied with the development of targeted therapies, especially potent TKIs.